Leerink Partnrs Analysts Lift Earnings Estimates for CSTL

Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q4 2024 earnings estimates for shares of Castle Biosciences in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings per share of $0.11 for the quarter, up from their prior forecast of $0.02. The consensus estimate for Castle Biosciences' current full-year earnings is $0.38 per share. Leerink Partnrs also issued estimates for Castle Biosciences' Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.06) EPS.

A number of other research firms also recently issued reports on CSTL. KeyCorp increased their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Stephens restated an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research note on Thursday, January 2nd. Robert W. Baird upped their price target on Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their price objective on Castle Biosciences from $35.00 to $42.00 and gave the stock a "buy" rating in a report on Tuesday, October 29th. Finally, Scotiabank boosted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $40.29.

Castle Biosciences Trading Down 0.5 %

NASDAQ:CSTL traded down $0.14 during trading hours on Thursday, hitting $26.48. The company had a trading volume of 118,164 shares, compared to its average volume of 557,855. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock has a 50-day moving average price of $28.66 and a 200 day moving average price of $28.18. The company has a market capitalization of $741.73 million, a PE ratio of 132.01 and a beta of 0.92. Castle Biosciences has a 52 week low of $16.97 and a 52 week high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The business had revenue of $85.78 million during the quarter, compared to analyst estimates of $78.55 million. During the same quarter in the prior year, the company posted ($0.26) EPS.

Institutional Trading of Castle Biosciences

Large investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in Castle Biosciences during the fourth quarter valued at approximately $42,000. Quest Partners LLC lifted its position in Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company's stock valued at $123,000 after purchasing an additional 1,522 shares in the last quarter. US Bancorp DE grew its holdings in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company's stock valued at $132,000 after purchasing an additional 4,383 shares during the period. Point72 DIFC Ltd purchased a new stake in Castle Biosciences in the third quarter worth about $140,000. Finally, Assetmark Inc. raised its stake in shares of Castle Biosciences by 16.8% in the third quarter. Assetmark Inc. now owns 5,212 shares of the company's stock worth $149,000 after buying an additional 748 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the transaction, the insider now directly owns 80,818 shares of the company's stock, valued at $2,265,328.54. This represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Tobin W. Juvenal sold 3,507 shares of Castle Biosciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total value of $124,708.92. Following the completion of the sale, the insider now owns 54,178 shares of the company's stock, valued at $1,926,569.68. The trade was a 6.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,306 shares of company stock worth $1,063,756 in the last quarter. Corporate insiders own 7.20% of the company's stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.